Therapeutic Drug Monitoring Market by Product (Consumable, Equipment (Immunoassay analyzer)), Technology (Fluorescence Immunoassay, Radioimmunoassay, GCMS), Class of drugs (Antibiotics, Bronchodilators), End User (Hospital Lab) - Global Forecast to 2023
Get in-depth analysis of the COVID-19 impact on the Therapeutic Drug Monitoring Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Therapeutic Drug Monitoring Market
Request For Special Pricing[141 Pages Report]The therapeutic drug monitoring market is projected to reach to reach USD 1.63 billion by 2023 from USD 1.16 billion in 2017 at a CAGR of 5.9% during the forecast period. The growth of this market is majorly driven by the rising number of organ transplant procedures and the use of TDM in traditional anticancer therapies. However, the lack of financial provisions for the clinical interpretation of TDM results is expected to restrain the growth of this market during the forecast period.
By Product, consumables segment was expected to account for a larger share in 2018.
The therapeutic drug monitoring products market is segmented into equipment and consumables. In 2018, the consumables segment was expected to account for a larger share of this market owing to the requirement of repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe as a result of the rising incidence of chronic and infectious diseases. Thermo Fisher Scientific (US), F. Hoffmann-La Roche (Switzerland), and Siemens Healthineers (Germany) are some of the key players operating in this market
By Technology, immunoassays segment is expected to account for the largest share in 2018
Based on technology, the therapeutic drug monitoring market is classified into immunoassays and chromatography-MS. The immunoassays segment is expected to account for the largest share of this market in 2018, mainly due to the increasing incidence of chronic and infectious diseases and technological innovation. Immunoassays are easy to perform and do not require specialized training. Most of the analyzers are automated, making them user-friendly; they also have rapid turnaround times, require smaller sample volumes, and are high-throughput. On the other hand, the interference of other biomolecules present in the sample is a major disadvantage associated with immunoassays. There is no single assay that can be used to test all molecules. For every new drug, a new assay must be developed that must be approved by the regulatory bodies in the region.
A key aspect of this market is that the analyzers offered by a company will only run with the same manufacturers assay reagents, which makes it difficult for smaller players to enter the market and also enables bigger players to retain their market share. Key players operating in this segment are F. Hoffmann-La Roche (Switzerland), Abbott (US), and Siemens Healthineers (Germany). The immunoassays market has been divided into chemiluminescent assays, fluorescence immunoassays, colorimetric immunoassays, radioimmunoassays, and others.
By Class of Drug, antiepileptic drugs segment is expected to account for the largest share of the therapeutic drug monitoring market in 2018
Based on the class of drugs, the therapeutic drug monitoring market is segmented into antiepileptic drugs, antibiotic drugs, immunosuppressant drugs, antiarrhythmic drugs, bronchodilator drugs, psychoactive drugs, and other drugs. The antiepileptic drugs segment is expected to account for the largest share of the therapeutic drug monitoring market in 2018. Antiepileptics are the most frequently monitored class of drugs due to their narrow therapeutic range and challenging pharmacokinetics. Antiepileptics, also known as anticonvulsants, are often prescribed for the treatment and management of seizures caused in conditions such as epilepsy and bipolar disorder. The most commonly monitored antiepileptic drugs include carbamazepine, ethosuximide, primidone, phenobarbital, phenytoin, and valproic acid.
Antiepileptics are the most commonly monitored class of drugs due to the high complexity and heterogeneity of epilepsy, lack of biological markers or specific clinical signs aside from the frequency of seizures to assess treatment efficacy or toxicity, and the highly complex pharmacokinetics of these drugs
By End User, hospitals dominated the market in 2018
On the basis of end user, the therapeutic drug monitoring market is categorized into hospital labs, commercial or private labs, and other end users.
The hospital laboratories segment is expected to account for a majority share in 2018. The large share of this segment is attributed to the fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories as they have the appropriate equipment as well as skilled staff to deliver clinically meaningful interpretations from TDM assays. Compared to reference laboratories, hospital laboratories are also more accessible and offer faster results
In 2018, North America is expected to account for the largest market share, followed by Europe
In this report, the therapeutic drug monitoring market, by region, has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018, North America is expected to account for the largest share of this market, followed by Europe. Growth in the North American market is mainly driven by the increasing per capita healthcare expenditure and the presence of technologically advanced healthcare infrastructure in the region. Initiatives taken by different government associations are also anticipated to boost market growth in the coming years.
The therapeutic drug monitoring market in the Asia Pacific is projected to register the highest growth rate of during the forecast period. Asian countries, particularly China, India, and Japan, show the highest growth rates in terms of healthcare spending. This, along with the rapidly growing geriatric population and increasing disposable income, makes Asia Pacific an attractive market for therapeutic drug monitoring. In addition, the increasing incidence of chronic diseases, such as diabetes, cancer, cardiovascular disease, and neurological disorders, creates further demand for therapeutic drug monitoring assays.
Market Dynamics
Driver:Use of TDM in traditional anticancer therapies
TDM provides valuable guidance for the dose adjustment of antibiotics, immunosuppressants, antiepileptics, and other drugs. However, its use in traditional anticancer therapies has been limited. The requirement of multiple blood samples to adequately define the systemic exposure of anticancer drugs is the major issue encountered while testing for anticancer therapies.
Drugs in blood samples have a short elimination half-life and are given by intermittent intravenous injections; this makes the entire monitoring process difficult to analyze. However, newer targeted anticancer therapies have different pharmacokinetic (PK) and dosing characteristics as compared with traditional cytotoxic drugs. Owing to this, it is now possible to estimate the steady-state drug exposure with a single trough-level measurement. Recent evidence indicates that certain PK parameters, including trough levels, are correlated with clinical outcomes for many cytotoxic agents, including imatinib, sunitinib, rituximab, and cetuximab. Although current evidence is not sufficient to make TDM a compulsory practice, investigations with encouraging results will have a practical place in the clinical care of patients with cancer. With the increasing incidence of cancer and focus on reducing the adverse effects of drugs, the monitoring of antineoplastic drugs is expected to gain more importance in the treatment of cancer.
Restraint: Reluctance of small hospitals to offer TDM services
The pressure on healthcare systems to provide services at the lowest possible cost has increased significantly across the globe over the last decade. This is a major factor restraining the growth of the TDM market because whether or not TDM services make a cost-effective contribution to patient care is still a debatable topic. Also, in developing countries, cost is a major factor limiting the use of TDM. In these countries, TDM services are offered in two settingsin large teaching hospitals (where the service is available through departments of clinical pharmacology) and in the private sector (where drug estimations are performed by clinical biochemistry departments).
Therapeutic drug monitoring involves the measurement of drug levels in patient samples and interpreting the test results to suggest dosing recommendations to physicians. Hospitals that provide therapeutic drug monitoring services only consider the cost of running the tests and ignore the cost of employing a team of clinical pharmacologists who add value to the therapeutic drug monitoring process. As a result, in most cases, a single technician is employed during normal working hours, owing to which therapeutic drug monitoring services are provided only five days a week and only during normal working hours. Also, as employing an entire team to provide drug monitoring services throughout the week proves to be too expensive for small hospitals, they rely on neighboring large hospitals that already have the services available.
Opportunity:Monitoring of biosimilars in autoimmune diseases
Anti-TNF-alpha biologics are proving to be an effective treatment for autoimmune diseases, such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). With the increasing healthcare costs as well as patent expirations, the number of R&D activities focusing on the development of biosimilars have increased over the last few years. The launch of biosimilars in the market is increasing the need for the better understanding of potential differences in biosimilar immunogenicity as well as their safety and efficacy profiles as compared to their precursors. For instance, TNF-alpha blockers, such as infliximab and adalimumab, both can trigger immunogenicity responses and researchers have hypothesized that their biosimilars drugs (CT-P13) may also promote immunogenicity. Therefore, it is vital to develop methods for the TDM of biosimilar drugs for autoimmune diseases to ensure effective patient care.
TDM assays provide a tool for measuring the drug level of CT-P13 (Remsima and Inflectra). The Infliximab Drug Level ELISA has been tested and shown to successfully cross-react with and accurately quantify levels of CT-P13 in patient samples. This will help the study of therapeutic biologic drug concentration optimization to understand how to avoid dose toxicity. Hence, combining TDM with biosimilar drugs will prove to be an effective strategy for improving the efficacy of biologics for the treatment of autoimmune diseases at an affordable cost.
Challenge: Operational barriers faced in conducting TDM tests
Clinical laboratories across major markets are still evolving. As a result, technicians face operational challenges in ensuring effective sample procurement, storage, and transportation, especially while adopting novel technologies such as chemiluminescent immunoassay, HPLC, and multiplex flow immunoassay (MFI). Laboratory space also needs to be reconfigured to meet the requirements of conducting specific immunoassay tests used for pathogen detection, as a means of avoiding cross-contamination and ensuring efficient time management. This results in considerable cost escalation to maintain and operate advanced immunoassay instruments, particularly those capable of handling a single sample type.
Due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the dearth of skilled laboratory technicians to operate advanced immunoassay diagnostic products is limiting their overall adoption, particularly in emerging markets. Also, the reluctance to move from manual operations towards automation is another major challenge for market growth. This is because many providers find it difficult to make the transition to IT-based approaches from manual or traditional approaches and may not prefer to make the shift at all.
Scope of the Report
|
Report Metric |
Details |
|
Market size available for years |
20162023 |
|
Base year considered |
2017 |
|
Forecast period |
20182023 |
|
Forecast units |
Million (USD) |
|
Segments covered |
By Product, By Technology, By Class of Drug, End User, By Geography |
|
Geographies covered |
North America (U.S., Canada), Europe, Asia-Pacific (Japan, China, India, Rest of Asia-Pacific), Rest of the World (RoW) |
|
Companies covered |
Abbott Laboratories, Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Biomιrieux, Bόhlmann Laboratories, Sekisui Medical, Randox Laboratories |
Key Market Players
Abbott Laboratories, Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Biomιrieux, Bόhlmann Laboratories, Sekisui Medical, Randox Laboratories.
Recent Developments
Critical questions the report answers:
- Who are the major market players in the therapeutic drug monitoring market?
- What are the growth trends and the largest revenue-generating region for therapeutic drug monitoring?
- How are therapeutic drug monitoring sold to customers?
- What are the major drug classes where therapeutic drug monitoring is used?
- What are the driving, restraining, opportunistic, and challenging factors for this market?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 15)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET COVERED
1.3.2 YEARS COVERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 18)
2.1 RESEARCH DATA
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3.1 KEY DATA SOURCES FROM SECONDARY SOURCES
2.3.2 KEY DATA FROM PRIMARY SOURCES
2.3.2.1 Key industry insights
3 EXECUTIVE SUMMARY (Page No. - 25)
4 PREMIUM INSIGHTS (Page No. - 28)
4.1 THERAPEUTIC DRUG MONITORING (TDM): MARKET OVERVIEW
4.2 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG
4.3 GEOGRAPHIC MIX: THERAPEUTIC DRUG MONITORING MARKET
4.4 THERAPEUTIC DRUG MONITORING MARKET, BY END USER
5 MARKET OVERVIEW (Page No. - 31)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Use of TDM in traditional anticancer therapies
5.2.1.2 Rising number of organ transplant procedures
5.2.2 RESTRAINTS
5.2.2.1 Reluctance of small hospitals to offer TDM services
5.2.3 OPPORTUNITIES
5.2.3.1 Monitoring of biosimilars in autoimmune diseases
5.2.4 CHALLENGES
5.2.4.1 Operational barriers faced in conducting TDM tests
6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT (Page No. - 34)
6.1 INTRODUCTION
6.2 CONSUMABLES
6.3 EQUIPMENT
6.3.1 IMMUNOASSAY ANALYZERS
6.3.2 CHROMATOGRAPHY AND MS DETECTORS
6.3.3 CLINICAL CHEMISTRY ANALYZERS
7 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY (Page No. - 42)
7.1 INTRODUCTION
7.2 IMMUNOASSAYS
7.2.1 CHEMILUMINESCENT IMMUNOASSAYS
7.2.2 FLUORESCENCE IMMUNOASSAYS
7.3 COLORIMETRIC IMMUNOASSAYS
7.4 RADIOIMMUNOASSAYS
7.5 OTHER IMMUNOASSAYS
7.6 CHROMATOGRAPHY-MS
7.6.1 LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY (LC-MS)
7.6.2 GAS CHROMATOGRAPHY-MASS SPECTROMETRY
8 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG (Page No. - 58)
8.1 INTRODUCTION
8.2 ANTIEPILEPTIC DRUGS
8.3 ANTIARRHYTHMIC DRUGS
8.4 IMMUNOSUPPRESSANT DRUGS
8.5 ANTIBIOTIC DRUGS
8.6 BRONCHODILATOR DRUGS
8.7 PSYCHOACTIVE DRUGS
8.8 OTHER DRUG CLASSES
9 THERAPEUTIC DRUG MONITORING MARKET, BY END USER (Page No. - 70)
9.1 INTRODUCTION
9.2 HOSPITAL LABORATORIES
9.3 COMMERCIAL/PRIVATE LABORATORIES
9.4 OTHER END USERS
10 THERAPEUTIC DRUG MONITORING MARKET, BY REGION (Page No. - 77)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 US
10.2.2 CANADA
10.3 EUROPE
10.4 ASIA PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 INDIA
10.4.4 ROAPAC
10.5 REST OF THE WORLD
11 COMPETITIVE LANDSCAPE (Page No. - 112)
11.1 INTRODUCTION
11.2 MARKET RANKING ANALYSIS
11.3 COMPETITIVE SITUATION AND TRENDS
11.3.1 PRODUCT LAUNCHES
11.3.2 MERGERS & ACQUISITIONS
12 COMPANY PROFILES (Page No. - 114)
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 ABBOTT LABORATORIES
12.2 F. HOFFMANN-LA ROCHE
12.3 SIEMENS HEALTHINEERS
12.4 THERMO FISHER SCIENTIFIC
12.5 DANAHER CORPORATION
12.6 BIO-RAD LABORATORIES
12.7 BIOMΙRIEUX
12.8 BάHLMANN LABORATORIES
12.9 SEKISUI MEDICAL
12.10 RANDOX LABORATORIES
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 135)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
LIST OF TABLES (145 TABLES)
TABLE 1 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 2 THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 3 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 4 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CONSUMABLES MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 5 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 6 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 7 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 8 THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 9 THERAPEUTIC DRUG MONITORING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION, 20162023 (USD MILLION)
TABLE 10 THERAPEUTIC DRUG MONITORING MARKET FOR CHROMATOGRAPHY AND MS DETECTORS, BY REGION, 20162023 (USD MILLION)
TABLE 11 THERAPEUTIC DRUG MONITORING MARKET FOR CLINICAL CHEMISTRY ANALYZERS, BY REGION, 20162023 (USD MILLION)
TABLE 12 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 13 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 14 THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 15 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 16 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 17 CLIA SYSTEMS AVAILABLE IN THE MARKET
TABLE 18 CHEMILUMINESCENT IMMUNOASSAYS MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 19 NORTH AMERICA: CHEMILUMINESCENT IMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 20 ASIA PACIFIC: CHEMILUMINESCENT IMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 21 FLUORESCENCE IMMUNOASSAYS MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 22 NORTH AMERICA: FLUORESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 23 ASIA PACIFIC: FLUORESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 24 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 25 NORTH AMERICA: COLORIMETRIC IMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 26 ASIA PACIFIC: COLORIMETRIC IMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 27 RADIOIMMUNOASSAYS MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 28 NORTH AMERICA: RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 29 ASIA PACIFIC: RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 30 OTHER IMMUNOASSAYS MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 31 NORTH AMERICA: OTHER IMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 32 ASIA PACIFIC: OTHER IMMUNOASSAYS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 33 THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 34 THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 35 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 36 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY-MS, BY COUNTRY, 20162023 (USD MILLION)
TABLE 37 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 38 NORTH AMERICA: LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 39 ASIA PACIFIC: LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 40 GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 41 NORTH AMERICA: GAS CHROMATOGRAPHY-MASS SPECTROMETRY MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 42 ASIA PACIFIC: GC-MS MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 43 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 44 GUIDELINES FOR THE MONITORING OF ANTIEPILEPTIC DRUGS
TABLE 45 ANTIEPILEPTIC DRUGS MONITORING MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 46 NORTH AMERICA: ANTIEPILEPTIC DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 47 ASIA PACIFIC: ANTIEPILEPTIC DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 48 ANTIARRHYTHMIC DRUGS MONITORING MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 49 NORTH AMERICA: ANTIARRHYTHMIC DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 50 ASIA PACIFIC: ANTIARRHYTHMIC DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 51 IMMUNOSUPPRESSANT DRUGS MONITORING MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 52 NORTH AMERICA: IMMUNOSUPPRESSANT DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 53 ASIA PACIFIC: IMMUNOSUPPRESSANT DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 54 ANTIBIOTIC DRUGS MONITORING MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 55 NORTH AMERICA: ANTIBIOTIC DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 56 ASIA PACIFIC: ANTIBIOTIC DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 57 THERAPEUTIC RANGES FOR BRONCHODILATORS
TABLE 58 BRONCHODILATOR DRUGS MONITORING MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 59 NORTH AMERICA: BRONCHODILATOR DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 60 ASIA PACIFIC: BRONCHODILATOR DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 61 PSYCHOACTIVE DRUGS MONITORING MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 62 NORTH AMERICA: PSYCHOACTIVE DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 63 ASIA PACIFIC: PSYCHOACTIVE DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 64 OTHER DRUGS MONITORING MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 65 NORTH AMERICA: OTHER DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 66 ASIA PACIFIC: OTHER DRUGS MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 67 THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 68 THERAPEUTIC DRUG MONITORING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2016-2023 (USD MILLION)
TABLE 69 NORTH AMERICA: THERAPEUTIC DRUG MONITORING FOR HOSPITAL LABORATORIES, BY COUNTRY, 20162023 (USD MILLION)
TABLE 70 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING FOR HOSPITAL LABORATORIES, BY COUNTRY, 20162023 (USD MILLION)
TABLE 71 THERAPEUTIC DRUG MONITORING MARKET FOR COMMERCIAL/PRIVATE LABORATORIES, BY REGION, 2013-2023 (USD MILLION)
TABLE 72 NORTH AMERICA: THERAPEUTIC DRUG MONITORING FOR COMMERCIAL/ PRIVATE LABORATORIES, BY COUNTRY, 20162023 (USD MILLION)
TABLE 73 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING FOR COMMERCIAL/ PRIVATE LABORATORIES, BY COUNTRY, 20162023 (USD MILLION)
TABLE 74 THERAPEUTIC DRUG MONITORING MARKET FOR OTHER END USERS, BY REGION, 2016-2023 (USD MILLION)
TABLE 75 NORTH AMERICA: THERAPEUTIC DRUG MONITORING FOR OTHER END USERS, BY COUNTRY, 20162023 (USD MILLION)
TABLE 76 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING FOR OTHER END USERS, BY COUNTRY, 20162023 (USD MILLION)
TABLE 77 THERAPEUTIC DRUG MONITORING MARKET, BY REGION, 20162023 (USD MILLION)
TABLE 78 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 79 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 80 NORTH AMERICA: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 81 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 82 NORTH AMERICA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 83 NORTH AMERICA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 84 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 85 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 86 US: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 87 US: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 88 US: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 89 US: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 90 US: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 91 US: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 92 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 93 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 94 CANADA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 95 CANADA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 96 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 97 CANADA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 98 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 99 EUROPE: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 100 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 101 EUROPE: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 102 EUROPE: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 103 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 104 EUROPE: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 105 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY COUNTRY, 20162023 (USD MILLION)
TABLE 106 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 107 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 108 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 109 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 110 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 111 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 112 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 113 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 114 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 115 JAPAN: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 116 JAPAN: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 117 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 118 JAPAN: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 119 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 120 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 121 CHINA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 122 CHINA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 123 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 124 CHINA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 125 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 126 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 127 INDIA: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 128 INDIA: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 129 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 130 INDIA: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 131 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 132 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 133 ROAPAC: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 134 ROAPAC: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 135 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 136 ROAPAC: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 137 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 20162023 (USD MILLION)
TABLE 138 ROW: THERAPEUTIC DRUG MONITORING EQUIPMENT MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 139 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 20162023 (USD MILLION)
TABLE 140 ROW: THERAPEUTIC DRUG MONITORING IMMUNOASSAYS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 141 ROW: THERAPEUTIC DRUG MONITORING CHROMATOGRAPHY & MS MARKET, BY TYPE, 20162023 (USD MILLION)
TABLE 142 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 20162023 (USD MILLION)
TABLE 143 ROW: THERAPEUTIC DRUG MONITORING MARKET, BY END USER, 20162023 (USD MILLION)
TABLE 144 PRODUCT LAUNCHES/APPROVALS, 20152018
TABLE 145 MERGERS & ACQUISITIONS, 20152018
LIST OF FIGURES (23 FIGURES)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 THERAPEUTIC DRUG MONITORING MARKET: TOP-DOWN APPROACH
FIGURE 3 THERAPEUTIC DRUG MONITORING MARKET: BOTTOM-UP APPROACH
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 5 DATA TRIANGULATION METHOD
FIGURE 6 THERAPEUTIC DRUG MONITORING MARKET, BY PRODUCT, 2018 VS. 2023 (USD BILLION)
FIGURE 7 THERAPEUTIC DRUG MONITORING MARKET, BY CLASS OF DRUG, 2018 VS. 2023 (USD MILLION)
FIGURE 8 THERAPEUTIC DRUG MONITORING MARKET, BY TECHNOLOGY, 2018 VS. 2023 (USD MILLION)
FIGURE 9 GEOGRAPHIC SNAPSHOT OF THE THERAPEUTIC DRUG MONITORING MARKET
FIGURE 10 GROWTH OF THIS MARKET IS MAJORLY DRIVEN BY THE RISING NUMBER OF ORGAN TRANSPLANT PROCEDURES
FIGURE 11 ANTIEPILEPTIC DRUGS WILL DOMINATE THE ASIA PACIFIC TDM CLASS OF DRUGS MARKET IN 2018
FIGURE 12 APAC TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 13 THERAPEUTIC DRUG MONITORING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 NORTH AMERICA: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
FIGURE 15 ASIA PACIFIC: THERAPEUTIC DRUG MONITORING MARKET SNAPSHOT
FIGURE 16 THERAPEUTIC DRUG MONITORING MARKET RANKING ANALYSIS, BY KEY PLAYER, 2017
FIGURE 17 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2017)
FIGURE 18 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017)
FIGURE 19 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2017)
FIGURE 20 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2017)
FIGURE 21 DANAHER CORPORATION: COMPANY SNAPSHOT (2017)
FIGURE 22 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2017)
FIGURE 23 BIOMΙRIEUX: COMPANY SNAPSHOT (2017)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Therapeutic Drug Monitoring Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Therapeutic Drug Monitoring Market